Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    Nanoveu Secures $2 Million to Fast-Track Commercial Launch of ECS-DoT Chip and AIoT Platform
    • News

  • Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    Archer Unlocks Cryogenic Sensor Breakthrough for Quantum Computing
    • News

  • EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    EGL Secures $1.9M PFAS Plant Contract as Demand for Clean-Up Technologies Surges
    • News

  • RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    RocketDNA Secures Major Aerial Tech Contract with Vault Minerals at WA Gold Site
    • News

  • BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    BirdDog Boosts Buy-Back Offer by 40% Ahead of ASX Delisting Vote
    • News

  • AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    AML3D Launches High-Tech U.S. Facility to Power Submarine Supply Chain
    • News

  • Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    Vection Enters $520K Agritech Deal to Build AI-Powered Farming Robot
    • News

  • Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    Unith Achieves Strong Growth in Platform Usage and Strategic Partnerships
    • News

  • FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    FBR and Samsung Heavy Industries Execute Engineering Service Agreement for Shipbuilding Automation Project
    • News

  • Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    Bioxyne Lifts FY2025 Revenue Forecast as Psychedelics and Pharma Push Gains Pace
    • News

Little Green Pharma enters race to treat mental illness with psychedelic medicines

  • In News
  • September 7, 2021
  • Alfred Chan
Little Green Pharma enters race to treat mental illness with psychedelic medicines

Advancing their research and development for medicinal cannabis applications, Little Green Pharma (ASX: LGP) has joined the global movement for use of psychedelics for treatment of mental illness having secured regulatory approval to supply psilocybin.

The approvals come in the form of a Schedule 9 licence granted by the WA Department of Health which enables Little Green Pharma to supply psilocybin to eligible licence holders.

Psilocybin is the primary substance within magic mushrooms which is known to cause hallucinations and is classified as a Schedule 9 drug. Once ingested, it induces a psychedelic state through its action on the brain’s 5HT-2A serotonin receptors. Its use as a treatment for mental illness was widely popularised in the 1970s with minimal research at the time when there was minimal regulation around its medicinal use.

With advancements in research however, and the global relaxation of regulation around cannabis for medicinal purposes, psychedelics are being explored by international researchers for its treatment properties to address depression, PTSD and anxiety.

Under Little Green Pharma’s program, the company will use psychedelics to assist psychotherapy.

“The field of psychedelics is a logical fit with our long term stated goals of solving real patient problems and transforming their lives,” said Little Green Pharma Managing Director, Fleta Solomon.

“We have developed so much experience over the years through the cannabis industry and we genuinely believe we can now bring that to bear on the development of the psychedelics field in Australia.

“The existing investment in our West Australian cannabis cultivation and manufacturing facility means we can meaningfully enter the field with minimal incremental capital spend.”

Securing the Schedule 9 licence overcomes the biggest hurdle to enter the psychedelics market and with it, Little Green Pharma will cultivate psilocybin mushrooms for use in medical research. This will leverage the Company’s existing cultivation operation in Western Australia where they already cultivate cannabis and manufacture cannabis products that are sold both domestically and internationally.

Driving their entry into the psychedelics market, Little Green Pharma has appointed Shaun Duffy as the CEO of their newly created subsidiary that focuses entirely on psychedelic medicine and its global developments. He will be assisted by Dr Stephen Bright who has joined in an advisory capacity, being a prominent and highly respected voice in the field of psychedelic medicine and a Senior Lecturer in Addiction at Edith Cowan University.

For FY21, Little Green Pharma reported a 219% increase in revenue to $7 million in a major year of growth for the Company which saw its products distributed to Germany, the United Kingdom, France, New Zealand and Brazil. New distribution agreements were also signed for Denmark, Poland and Lithuania.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  •  
  •  
  •  
  •  
  • asx lgp
  • Fleta Solomon
  • lgp
  • Little green pharma
  • psilocybin
  • ptsd
  • stephen bright
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.